- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05268289
Étude de l'efficacité et de l'innocuité de LNP023 chez des participants atteints de néphrite lupique active de classe III-IV, +/- V
Un essai adaptatif, randomisé, en double aveugle, d'exploration de dose, en groupes parallèles, contrôlé par placebo, multicentrique de phase 2 pour évaluer l'efficacité, l'innocuité et la tolérabilité de LNP023 en association avec la norme de soins avec et sans corticostéroïdes oraux chez les patients atteints de lupus actif Néphrite Classe III-IV, +/- V
The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
-
Mainz, Allemagne, 55131
- Novartis Investigative Site
-
-
Lower Saxony
-
Braunschweig, Lower Saxony, Allemagne, 38126
- Novartis Investigative Site
-
-
North Rhine-Westphalia
-
Cologne, North Rhine-Westphalia, Allemagne, 51109
- Novartis Investigative Site
-
-
-
-
-
Santa Fe, Argentine, S3000EPV
- Novartis Investigative Site
-
-
-
-
-
Salvador, Brésil, 40323-010
- Novartis Investigative Site
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brésil, 40150-150
- Novartis Investigative Site
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brésil, 30150-221
- Novartis Investigative Site
-
Juiz de Fora, Minas Gerais, Brésil, 36010-570
- Novartis Investigative Site
-
-
São Paulo
-
Barretos, São Paulo, Brésil, 14784-400
- Novartis Investigative Site
-
São Paulo, São Paulo, Brésil, 05403-000
- Novartis Investigative Site
-
São Paulo, São Paulo, Brésil, 04038-002
- Novartis Investigative Site
-
São Paulo, São Paulo, Brésil, 01308-050
- Novartis Investigative Site
-
-
-
-
-
Beijing, Chine, 100034
- Novartis Investigative Site
-
Shenzhen, Chine, 518036
- Novartis Investigative Site
-
-
Guangxi
-
Nanning, Guangxi, Chine, 530022
- Novartis Investigative Site
-
-
Hubei
-
Wuhan, Hubei, Chine, 430022
- Novartis Investigative Site
-
-
Liaoning
-
Shenyang, Liaoning, Chine, 110004
- Novartis Investigative Site
-
-
Ningxia
-
Yinchuan, Ningxia, Chine, 750004
- Novartis Investigative Site
-
-
-
-
-
Montería, Colombie, 230004
- Novartis Investigative Site
-
-
Atlántico
-
Barranquilla, Atlántico, Colombie, 080020
- Novartis Investigative Site
-
-
Cundinamarca
-
Bogota, Cundinamarca, Colombie, 111411
- Novartis Investigative Site
-
-
Santander Department
-
Bucaramanga, Santander Department, Colombie, 680003
- Novartis Investigative Site
-
-
-
-
-
Barcelona, Espagne, 08036
- Novartis Investigative Site
-
Ciudad Real, Espagne, 13005
- Novartis Investigative Site
-
Madrid, Espagne, 28034
- Novartis Investigative Site
-
Madrid, Espagne, 28040
- Novartis Investigative Site
-
Seville, Espagne, 41009
- Novartis Investigative Site
-
-
-
-
-
Marseille, France, 13005
- Novartis Investigative Site
-
Nantes, France, 44093
- Novartis Investigative Site
-
-
-
-
Hong Kong
-
Hong Kong, Hong Kong, Hong Kong, 999077
- Novartis Investigative Site
-
-
-
-
-
Budapest, Hongrie, 1083
- Novartis Investigative Site
-
Szeged, Hongrie, 6725
- Novartis Investigative Site
-
-
Hajdu Bihar Megye
-
Debrecen, Hajdu Bihar Megye, Hongrie, 4032
- Novartis Investigative Site
-
-
-
-
Kerala
-
Kozhikode, Kerala, Inde, 673008
- Novartis Investigative Site
-
-
National Capital Territory of Delhi
-
New Delhi, National Capital Territory of Delhi, Inde, 110029
- Novartis Investigative Site
-
-
Telangana
-
Hyderabad, Telangana, Inde, 500082
- Novartis Investigative Site
-
-
Uttar Pradesh
-
Lucknow, Uttar Pradesh, Inde, 226014
- Novartis Investigative Site
-
-
-
-
-
Carnaxide, Le Portugal, 2799-523
- Novartis Investigative Site
-
Coimbra, Le Portugal, 3004-561
- Novartis Investigative Site
-
Lisbon, Le Portugal, 1649-035
- Novartis Investigative Site
-
Vila Nova de Gaia, Le Portugal, 4434-502
- Novartis Investigative Site
-
-
-
-
-
Selangor Darul Ehsan, Malaisie, 68100
- Novartis Investigative Site
-
-
Pahang
-
Kuantan, Pahang, Malaisie, 25100
- Novartis Investigative Site
-
-
Perak
-
Taiping, Perak, Malaisie, 34000
- Novartis Investigative Site
-
-
-
-
-
Aguascalientes, Mexique, 20230
- Novartis Investigative Site
-
Veracruz, Mexique, 91900
- Novartis Investigative Site
-
-
Tamaulipas
-
Tampico, Tamaulipas, Mexique, 89440
- Novartis Investigative Site
-
-
Yucatán
-
Mérida, Yucatán, Mexique, 97070
- Novartis Investigative Site
-
-
-
-
-
Quezon, Philippines, 1102
- Novartis Investigative Site
-
-
National Capital Region
-
Makati City, National Capital Region, Philippines, 1218
- Novartis Investigative Site
-
-
-
-
-
San Juan, Porto Rico, 00927
- FDI Clinical Research
-
-
-
-
-
Cambridge, Royaume-Uni, CB2 0QQ
- Novartis Investigative Site
-
-
-
-
Singapore
-
Singapore, Singapore, Singapour, 308433
- Novartis Investigative Site
-
-
-
-
Fatih
-
Istanbul, Fatih, Turquie (Türkiye), 34093
- Novartis Investigative Site
-
-
Melikgazi
-
Kayseri, Melikgazi, Turquie (Türkiye), 38039
- Novartis Investigative Site
-
-
Nilufer
-
Bursa, Nilufer, Turquie (Türkiye), 16059
- Novartis Investigative Site
-
-
Yenimahalle
-
Ankara, Yenimahalle, Turquie (Türkiye), 06500
- Novartis Investigative Site
-
-
Yenisehir
-
Mersin, Yenisehir, Turquie (Türkiye), 33110
- Novartis Investigative Site
-
-
-
-
California
-
Los Angeles, California, États-Unis, 90095
- Ronald Reagan UCLA Medical Center
-
San Bernardino, California, États-Unis, 92408
- Loma Linda University
-
Sylmar, California, États-Unis, 91342
- Olive View UCLA Medical Center
-
-
Colorado
-
Aurora, Colorado, États-Unis, 80045
- University of Colorado Denver
-
-
Florida
-
Hollywood, Florida, États-Unis, 33021
- Royal Research Corp
-
Orlando, Florida, États-Unis, 32806
- Nephrology Associates Of Central FL
-
Riverview, Florida, États-Unis, 33578
- Florida Kidney Physicians
-
-
Illinois
-
Hinsdale, Illinois, États-Unis, 60521
- Nep Assoc of Northern Illinois
-
-
Kansas
-
Wichita, Kansas, États-Unis, 67214
- Wichita Community Clcl Onco Program
-
-
Louisiana
-
New Orleans, Louisiana, États-Unis, 70121
- Ochsner Health System
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21287
- Johns Hopkins Hospital
-
-
New York
-
East Setauket, New York, États-Unis, 11733
- Stony Brook Internists PC
-
-
Ohio
-
Cleveland, Ohio, États-Unis, 44195
- Cleveland Clinic Foundation
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19140
- Temple University
-
-
Texas
-
Dallas, Texas, États-Unis, 75204
- Dallas Nephrology Associates
-
Houston, Texas, États-Unis, 77054
- Prolato Clinical Research Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
Unequivocally positive ANA test result and/or a positive anti dsDNA at screening Active biopsy-proven lupus nephritis within 3 months of screening demonstrating Class III or IV lupus nephritis with or without co-existing features of Class V lupus nephritis.
Documentation of active renal disease at the time of screening necessitating the commencement of therapy with corticosteroids in combination with MMF/MPS.
eGFR ≥ 30 ml/min/1.73 m2 Vaccination against Neisseria meningitidis and Streptococcus pneumoniae infections Vaccination against Haemophilus influenzae infection Supportive care including stable dose regimen of anti-malarials (e.g. hydroxychloroquine) unless contraindicated, ACEi or ARB at either locally approved maximal daily dose or the maximally tolerated dose (per investigators' judgement) at screening, as per the local clinical practice. Doses should remain stable throughout the study.
First presentation or flare of lupus nephritis.
Exclusion Criteria:
Induction treatment with cyclophosphamide within 3 months of planned treatment for this study; treatment with calcineurin inhibitors within the previous 3 months prior to randomization.
Presence of rapidly progressive glomerulonephritis (RPGN) as defined by 50% decline in eGFR within 3 months prior to screening.
Renal biopsy presenting with interstitial fibrosis/tubular atrophy (IF/TA) or glomerulosclerosis of more than 50%, or which in the opinion of the investigator is such that it precludes likely response to immunosuppressive therapy.
Participants being treated with systemic corticosteroids (>5 mg/day prednisone or equivalent) for indications other than SLE or LN e.g. acute asthma, inflammatory bowel disease.
Participants being treated with systemic corticosteroids for SLE or LN will be excluded if they have taken more than an average of 15 mg/day prednisone (or equivalent) in the previous 4 weeks and more than an average of 30 mg/day in the previous 1 week Receipt of more than a total dose of 1000 mg equivalent i.v. pulse methylprednisolone (cumulative dose) within 2 weeks prior to enrollment (and at enrollment)
Other protocol-defined inclusion/exclusion criteria may apply
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation séquentielle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Iptacopan + standard of care (part 1)
Iptacopan + standard of care |
Taken for 52 Weeks
Autres noms:
|
|
Comparateur placebo: Placebo matching iptacopan + standard of care (part 1)
Placebo matching iptacopan standard of care |
Taken for 52 Weeks |
|
Comparateur actif: Iptacopan + standard of care (part 2)
Iptacopan + standard of care |
Taken for 52 Weeks
Autres noms:
|
|
Comparateur actif: Iptacopan + placebo (part 2)
Iptacopan + placebo standard of care |
Taken for 52 Weeks
Autres noms:
|
|
Comparateur actif: Placebo matching iptacopan + standard of care (part 2)
Placebo matching iptacopan + standard of care |
Taken for 52 Weeks |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Part 1 and 2: Proportion of patients achieving Complete Renal Response (CRR) at week 24 in the absence of renal flares
Délai: Baseline and week 24
|
Part 1: To evaluate the proportion of patients achieving complete renal response with iptacopan treatment "A" plus standard of care, compared to treatment alone Part 2: To evaluate the proportion of patients achieving complete renal response with Iptacopan treatment "B" plus standard of care, compared to treatment "D" alone Part 2: To evaluate the proportion of patients achieving complete renal response with Iptacopan treatment "C" plus standard of care, compared to treatment "D" alone Complete Renal Response is defined as meeting the following criteria: estimated glomerular filtration rate (eGFR) ≥ 90 mL/min/1.73 m2 or no less than 85% of baseline value, and 24h urine protein-to-creatinine ratio (UPCR) ≤ 0.5 g/g. |
Baseline and week 24
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Parts 1 and 2: Proportion of patients achieving CRR or PRR in the absence of renal flares
Délai: Baseline, week 24, week 52
|
Proportion of patients achieving complete renal response or partial renal response |
Baseline, week 24, week 52
|
|
Proportion of patients achieving ≥25% UPCR reduction in the absence of renal flares compared to baseline at week 24
Délai: Baseline, week 24 week 52
|
Frequency of renal flares between weeks 24 and 52 |
Baseline, week 24 week 52
|
|
Log-transformed ratio to baseline of 24h UPCR at week 24
Délai: Baseline week 24
|
Dose exposure response for reduction in proteinurea. (each 24h urine protein-to-creatinine ratio value will based on two 24 urine collections sampled within 10 days before the respective study visit) |
Baseline week 24
|
|
Change from baseline FACIT-Fatigue Score
Délai: Weeks 24 and 52
|
Measure fatigue in patients |
Weeks 24 and 52
|
|
Change from baseline in SLEDAI-2K score at weeks 24 and 52
Délai: Weeks 24 and 52
|
Measure disease activity in SLE |
Weeks 24 and 52
|
|
Change from baseline in BILAG-2004 score at weeks 24 and 52
Délai: Weeks 24 and 52
|
Measure disease activity |
Weeks 24 and 52
|
|
Time-to-Complete Renal Response (CRR) based on first morning void(FMV) urine samples
Délai: Week 24 and Week 52
|
Measurement of time to complete renal response based on urine samples |
Week 24 and Week 52
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Maladies urogénitales masculines
- Maladies rénales
- Maladies urologiques
- Maladies urogénitales féminines
- Maladies urogénitales féminines et complications de la grossesse
- Maladies du tissu conjonctif
- Maladies auto-immunes
- Maladies du système immunitaire
- Troubles urinaires
- Manifestations urologiques
- Glomérulonéphrite
- Néphrite
- Conditions pathologiques, signes et symptômes
- Maladies de la peau et du tissu conjonctif
- Signes et symptômes
- Lupus érythémateux systémique
- Néphrite lupique
- Protéinurie
- Administration des services de santé
- Qualité des soins de santé, accès et évaluation
- Qualité des soins de santé
- Indicateurs de qualité, soins de santé
- Standard de soins
- iptacopan
Autres numéros d'identification d'étude
- CLNP023K12201
- 2021-002046-33 (Numéro EudraCT)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .